

R&D COLLABORATIVE PROPOSAL / **COMPANY PARTNER SEARCH**

The information you are about to provide in this form will be distributed among Spanish companies matching your company profile and that might be interested in the proposal of collaborative R&D project that you will be describing in this form.
(Please use English language for filling in the document)

In the case that your company will establish a R&D project in collaboration with a Spanish company, your partner could benefit from the preferential financing given by CDTI under the frame of their International Cooperation Programs.



Company name: Uni-TongXin Biotech Co., Ltd

WEB site: www.uni-biotech.com

Number of employees: Approximately 50 employees

Year of Establishment: 2004

Activity/ sector: Biotechnology

Key products and/or services: Biotech Medical, Health Supplements, and Topical Skincare products.

Annual turnover: Approx. USD 5.3 Million (NTD 170 Million)

Balance Total: Approx. USD 11.8 Million (NTD 380 Million)

Address: No. 71, Keji 5th Rd.

City: Annan Dist., Tainan City

Province: Taiwan, R. O. C

Postal Code: 70955

Telephone: +886-6-3841000

Fax: +886-6-3841171

Email:

Contact: Manager

Position: Po-Yung Chen

Telephone: +886-6-3841000#610

Email: tx1040804@unibiotech.com.tw

Additional Contact: Dean of R&D

Position: Nielsen FengYi Shen

Telephone: +886-6-3841000#600

Email: chanpowin@unibiotech.com.tw

YOUR COMPANY DESCRIPTION

(Activity description, main markets, strategic alliances, competitive position, share (%) of turnover due to exports, R&D resources and investment, partnerships with other companies or research organization, previous relationship with Taiwanese national R&D institutions, etc)

Uni-TongXin Biotech Co., Ltd., established in 2004, is a Taiwan-based biotechnology company specializing in the research, development, and application of bioactive compounds derived from traditional Chinese herbal medicine. The company was founded with investment from the Chuang Song Zong Pharmaceutical Group and integrates traditional Chinese medicine theories with modern Western medical, pharmaceutical, and biotechnological approaches to transform classical herbal formulas into scientifically validated, data-driven, and internationally competitive products.

The company's core competencies include herbal active compound extraction, ingredient profiling and quality control, cell-based and functional evaluation assays, skin penetration and topical safety testing, as well as natural product fermentation, synbiotic, and postbiotic technology platforms. Manufacturing operations are conducted under ISO 22000 and HACCP certified environments, in close collaboration with GMP-certified pharmaceutical manufacturers, ensuring smooth scale-up from R&D to high-quality commercial production.

Uni-TongXin Biotech's primary markets include Taiwan and other Asian regions, with continuous expansion into international OEM/ODM and ingredient licensing collaborations. The company places strong emphasis on R&D investment and maintains long-term partnerships with universities, research institutes, and public research organizations. It actively participates in national innovation programs such as SBIR. To date, the company has obtained more than 20 domestic and international patents, as well as over 20 awards and professional certifications, establishing a solid technological and market position in herbal health supplements, topical repair products, and functional bio-ingredients.

COLLABORATIVE R&D PROJECT PROPOSAL

(Describe as precisely as possible the technology cooperation proposal and your main motivation, describe what you have to offer and what you expect from your potential Spanish partner from a technical point of view and from a commercial point of view, describe the profile of the Spanish company that you request, describe if you have previous contact with Spanish companies, additional comments)

In the field of functional herbal ingredients, Uni-TongXin Biotech Co., Ltd. has successfully developed a representative multi-herbal formulation, Kam.Pain. Kam.Pain is a standardized composite formula consisting of 13 traditional Chinese medicinal herbs and does not contain any Western pharmaceutical or synthetic drug ingredients. The formulation is based on traditional herbal medicine principles and has been further developed through modern scientific approaches, including compositional analysis, quality control, and functional validation.

Kam.Pain is designed primarily for anti-inflammatory, anti-swelling, and pain-relief applications, with a strategic focus on topical product development,

including liquid formulations, ointments, gels, and transdermal patches. Medical device adjunct applications represent the secondary development priority, while health or functional products are considered a longer-term extension.

To date, Kam.Pain has completed the following key R&D and validation milestones:

- A. Composition and Quality
 - Basic compositional profiling and identification of marker compounds
 - Establishment of batch-to-batch consistency and preliminary quality control parameters
- B. Safety Evaluation
 - Completion of preliminary topical safety assessments, including skin irritation and usage safety evaluations
 - No significant adverse reactions or side effects observed during clinical use
- C. Efficacy and Application Validation
 - Initial functional evaluations demonstrating anti-inflammatory and symptom-relief potential
 - Development primarily in a transdermal patch dosage form, with successful completion of Phase II clinical trials
 - Clinical outcomes demonstrated significant improvement in lower back pain symptoms, with favorable safety and tolerability profiles

Taken together, Kam.Pain demonstrates a comprehensive development foundation from ingredient characterization and formulation to clinical-stage validation, indicating a high level of readiness for international collaborative R&D, EU-oriented technical validation, and translational product development.

SPANISH PARTNERS

(if you know a potential Spanish company, write its name and contact details in this section. CDTI will contact them to evaluate their willingness to meet with you)

This collaborative R&D proposal is centered on Kam.Pain, a proprietary multi-herbal ingredient developed by Uni-TongXin Biotech with an established clinical validation foundation. The project aims to establish an international collaboration with Spanish companies experienced in biotechnology, pharmaceuticals, or medical device R&D.

The application priority of this collaboration is defined as follows:

- A. Topical applications (Primary focus)
Co-development and commercialization of liquid formulations, ointments, gels, and transdermal patches
- B. Medical device adjunct applications (Secondary focus)
Functional ingredient integration into medical device-related or pain management products
- C. Health / functional products (Future expansion)

Uni-TongXin Biotech will provide the Kam.Pain formulation, manufacturing and quality control know-how, existing safety and clinical trial data, and integrated

expertise combining traditional herbal medicine with modern scientific validation.

Key collaboration objectives include:

- Advanced safety and efficacy validation aligned with EU regulatory requirements
- Co-development of novel topical and medical device-related dosage forms
- Localization and optimization of formulations or delivery systems for European markets
- Joint planning of preclinical and clinical development strategies

Preferred collaboration models are:

- Primary: OEM / ODM-based collaboration (co-development and manufacturing)
- Secondary: Technology licensing arrangements (by application field or geographic market)

The ideal Spanish partner would possess strong R&D capabilities in biotechnology, pharmaceuticals, or medical devices, with experience in EU regulatory frameworks, clinical development, or market commercialization.

Through CDTI international cooperation programs, both parties aim to leverage preferential financing to reduce development risk and establish a sustainable long-term technological and commercial partnership.